ArticleEJNMMI radiopharmacy and chemistry2017
Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Article in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Beyond bisphosphonates: radiolabeled phosphopeptides for bone targeting.EJNMMI research · 2026Article
- Theranostics of Bone Metastases: The Role and Prospects of Bisphosphonate Radiopharmaceuticals.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Towards Optimal AutomatedJournal of labelled compounds & radiopharmaceuticals · 2024Article
- Diagnosis of periprosthetic loosening of total hip and knee arthroplasty usingArchives of orthopaedic and trauma surgery · 2024Article
- Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy.International journal of molecular sciences · 2023Review
- Article
- Preparation, Optimisation, and In Vitro Evaluation of [Molecules (Basel, Switzerland) · 2022Article
- Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.Theranostics · 2022Review
- Preparation, biological characterization and preliminary human imaging studies ofFrontiers in oncology · 2022Article
- Squaric Acid Bisphposphonates for Theranostics of Bone Metastasis - the Easy DOTA-Zoledronate.Frontiers in nuclear medicine · 2022Article
- DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.Frontiers in nuclear medicine · 2022Article
- [Bioconjugate chemistry · 2021Article
- Article
- A review of advances in the last decade on targeted cancer therapy usingAmerican journal of nuclear medicine and molecular imaging · 2021Review
- [EJNMMI research · 2020Article
- DOTA-ZOL: A Promising Tool in Diagnosis and Palliative Therapy of Bone Metastasis-Challenges and Critical Points in Implementation into Clinical Routine.Molecules (Basel, Switzerland) · 2020Article
- Preparation, Characterization, and Radiolabeling of [Molecules (Basel, Switzerland) · 2020Article
- Biodistribution and post-therapy dosimetric analysis of [EJNMMI research · 2019Article
- Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging.EJNMMI research · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBisphosphonates have a high adsorption on calcified tissues and are commonly used in the treatment of bone disorder diseases. Conjugates of bisphosphonates with macrocyclic chelators open new possibilities in bone targeted radionuclide imaging and therapy. Subsequent to positron emission tomography (PET) examinations utilizing
methodsBased on the established pharmaceuticals pamidronate and zoledronate two new DOTA-α-OH-bisphosphonates, DOTA
resultsThe new DOTA-bisphosphonates can be labelled in high yield of 80 to 95 % in 15 min with post-processed
conclusionThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.